Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
US FDA approves J&J's bladder cancer treatment
04:28pm, Tuesday, 09'th Sep 2025
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative
U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
04:18pm, Tuesday, 09'th Sep 2025
First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinductio
Are You Looking for a High-Growth Dividend Stock?
12:46pm, Tuesday, 09'th Sep 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson: JNJ Stock To $250?
10:20am, Tuesday, 09'th Sep 2025
Johnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance grounded
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
04:25pm, Monday, 08'th Sep 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fires
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
10:15am, Monday, 08'th Sep 2025
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout
08:01am, Monday, 08'th Sep 2025
I reiterate my buy rating on JNJ, supported by steady EPS growth, robust free cash flow, and an attractive valuation. Recent quarterly results beat expectations, with management raising guidance and a
Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market
04:05am, Monday, 08'th Sep 2025
This company boasts a strong history of dividend growth, making it attractive for income-focused investors. Currently, the stock appears slightly undervalued, but a clear catalyst is needed for it to
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RAR
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
07:00pm, Saturday, 06'th Sep 2025
Explore the exciting world of Johnson & Johnson (JNJ -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into mark
RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment BARCELONA, Spain , Sept. 6, 2025 /PRNewswire/ -- John
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
02:07am, Saturday, 06'th Sep 2025
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
04:09am, Thursday, 04'th Sep 2025
The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching c
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
04:29pm, Wednesday, 03'rd Sep 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaq
